THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
James Atwood, General Manager, Applied GenomicsPerkinElmer offers a comprehensive, integrated solution that includes all of the above prerequisites to achieve such operational coherence among these disparate laboratory workflow elements, thereby bringing true automation and consistency to the laboratory. By limiting manual interactions, including hand pipetting, the efficiency of the genomic workflow is collectively improved. As a complete solution, PerkinElmer showcases enormous value to automation solutions by nurturing a fundamental understanding of the entire experimental workflow to create the reagents that fit each client’s purpose.
The firm has developed technologies that support ‘eight-channel variable spanning heads,’
An example of the JANUS G3 liquid handler’s applicability can be seen in their recent collaboration with Oxford Immunotec. During this collaboration, the JANUS G3 liquid handlers enabled Oxford Immunotec to proceed with its plans to automate its testing workflows and allow its customers to migrate to automated laboratory processes. Facilitating such workflow automation for various firms and laboratories, PerkinElmer considers customer relationships as their highest priority.
To cater to customers’ growing needs, the firm launched its PKeye mobile operations monitor, enabling true walk-away automation while using their liquid handlers. The PKeye monitor includes a set of cameras that are mounted on the instrument, in addition to cloud-based software that monitors the instrument status and log files in real-time. Any alert triggered during the process is passed up to the secure cloud-based website controlled by the lab manager and then passed down to the lab technician’s cell phone. This process allows a lab technician to remain away from the instrument while running and still get notified when manual intervention is needed. “The PKeye monitor takes the benefit of a liquid handler and dramatically improves it. It allows you to walk away from the product while it’s running,” concludes James.
Company
PerkinElmer
Management
James Atwood, General Manager, Applied Genomics
Description
PerkinElmer brings enormous value to automation solutions by offering instrumentation, reagents, consumables, and software around the experimental workflow. PerkinElmer offers a comprehensive, integrated solution that includes all of the above prerequisites to achieve such operational coherence among these disparate laboratory workflow elements, thereby bringing true automation and consistency to the laboratory. The engineering teams that support the instrumentation are backed up by scientists specializing in internal applications development.
As precision medicine gathers pace for personalized disease treatment and prevention, Covaris is ideally positioned to help enable and accelerate the next generation of life sciences innovation, especially through its Next-Generation Sequencing (NGS) capability, for efficient, reproducible and high-throughput sample preparation and data analysis. Founded in 1999 and headquartered in Woburn, Massachusetts, Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis, including instruments, consumables, and reagents. Covaris’ solutions empower customers to accelerate the pace of research and drug discovery for clinical diagnostics, biopharma, and research markets globally.
“Covaris has a well-defined growth strategy with market-leading technologies and a very capable leadership team that will allow PerkinElmer to deepen its life sciences portfolio in the diagnostics end market. We see significant growth opportunities resulting from the combined resources of both companies, with PerkinElmer’s global scale unlocking commercial opportunities for Covaris,” said Dirk Bontridder, CEO of PerkinElmer.
“We are excited to begin our new chapter as part of PerkinElmer, an exceptional brand that resonates in our core markets, and will allow us to bring our technology to more customers and expand our growth globally. Our two cultures are very similar and both our customers as well as our employees will benefit from strong R&D resources and complementary solution capabilities,” said Annemarie Watson, CEO of Covaris.
Andre Moura, Managing Director at New Mountain Capital, said, “The combination of PerkinElmer and Covaris will bring significant benefits to the customers, employees, and stakeholders of both companies. Covaris will now have access to PerkinElmer’s global reach, technical and operating capabilities to continue its rapid growth trajectory. Covaris’ strong position in the genomics, transcriptomics, and proteomics space brings an exciting new growth vector to PerkinElmer. We look forward to continuing to work with management to build the combined company.”